Studies have shown that downregulation of p16 gene expression resulted in the loss of its inhibitory effects on CDK4/CDK6, which in turn may lead to malignant, abnormal cell proliferation and accelerated tumor development [7, 46, 47]. The gene discussed is CDKN2A; the disease is neoplasm.